Preparation for improving Parkinson's disease treatment effect of exosome and application
The treatment of stem cell exosomes by acetylated purslane polysaccharides has solved the problem of poor efficacy in common exosome treatment, significantly improving the efficacy of Parkinson's disease treatment, especially in the improvement of motor coordination and autonomous activity levels. Shows potential in neural repair.
Patent Information
- Application Number
- CN202411261427.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-12-06
AI Technical Summary
Untreated common exosomes cannot achieve ideal therapeutic effects in Parkinson's disease treatment, mainly because the concentration of therapeutic substances carried is limited and it is difficult to have a significant effect in nerve repair and protection.
The stem cell exosomes are treated with acetylated purslane polysaccharide, and the concentration of therapeutic substances in the exosomes are increased through specific preparation methods and their efficacy in the treatment of Parkinson's disease.
It significantly improved the efficacy of exosomes in improving Parkinson's symptoms, especially in improving motor coordination, balance ability and autonomous activity levels, demonstrating excellent results in neurorepair.
Smart Images

Figure CN119082006A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of neuromedicine, and in particular relates to a preparation and application for improving the therapeutic effect of exosomes on Parkinson's disease. Background Art
[0002] Parkinson's disease (PD) is a common neurodegenerative disease that mainly affects the motor function of the central nervous system. It is characterized by the gradual loss of dopaminergic neurons in the substantia nigra, leading to clinical symptoms such as tremor, muscle rigidity, bradykinesia and postural instability. Although the cause of Parkinson's disease has not yet been fully clarified, current studies have shown that oxidative stress plays an important role in the pathogenesis of the disease. With the intensification of the global aging problem, the incidence of Parkinson's disease has increased year by year. Therefore, how to effectively treat the disease has become a medical problem that needs to be solved urgently.
[0003] Exosomes are small vesicles with a diameter of about 30-150 nanometers, which are secreted by cells into the extracellular environment and widely exist in body fluids. As an important medium for intercellular communication, exosomes can carry and deliver a variety of bioactive substances, such as proteins, lipids, mRNA, miRNA, etc., and then play a regulatory role in the receiving cells. In recent years, exosomes have shown broad application prospects in the treatment of Parkinson's disease due to their unique biological functions and targeting. Studies have shown that the delivery of neurotrophic factors or anti-inflammatory factors through exosomes can promote neuronal survival and functional recovery in Parkinson's patients to a certain extent. In addition, exosomes also have the ability to cross the blood-brain barrier, making them an ideal neurotherapy carrier.
[0004] However, unprocessed ordinary exosomes often fail to achieve the desired therapeutic effect in the treatment of Parkinson's disease. This is mainly because the concentration of therapeutic substances carried by ordinary exosomes is limited, making it difficult to produce significant effects in nerve repair and protection. Therefore, how to enhance the therapeutic effect of exosomes has become the key to improving the treatment strategy for Parkinson's disease. Summary of the invention
[0005] The purpose of the present invention is to provide a preparation and application that can effectively enhance the therapeutic effect of exosomes on Parkinson's disease, thereby effectively enhancing the therapeutic effect of exosomes.
[0006] To achieve the above object, the present invention provides the following technical solutions:
[0007] Firstly, the present invention provides an application of an acetylated polysaccharide in the preparation of a pharmaceutical preparation for improving the therapeutic ability of stem cell exosomes for Parkinson's disease, wherein the acetylated polysaccharide is acetylated purslane polysaccharide.
[0008] Preferably, the preparation method of the acetylated purslane polysaccharide comprises the following steps:
[0009] (1) preparing a purslane polysaccharide solution using distilled water;
[0010] (2) adjusting the pH to 8, adding acetic anhydride according to the solid-liquid ratio of purslane polysaccharide to acetic anhydride of 1:10, and controlling the pH of the reaction system in the range of 8-8.5 during the addition process;
[0011] (3) After reacting for 2.5 h, the pH was adjusted to 7 to terminate the reaction to obtain reaction solution a;
[0012] (4) Concentrating the reaction solution a to 1 / 4 of the original volume to obtain a concentrated solution;
[0013] (5) After deproteinization with Sevage reagent, add 4 times the volume of anhydrous ethanol of the concentrate, stir evenly, and leave overnight;
[0014] (6) After centrifugation, the precipitate is separated and washed with ethanol;
[0015] (7) The washed precipitate is freeze-dried in vacuum to obtain acetylated purslane polysaccharide powder.
[0016] Preferably, the preparation method of purslane polysaccharide comprises the following steps:
[0017] (1) Place dried purslane into an extraction container and add distilled water at a ratio of 1:15;
[0018] (2) heating the extraction container to 80°C, maintaining the temperature and stirring continuously for 3 hours, filtering, and collecting the residue and filtrate a;
[0019] (3) Place the residue into an extraction container and add distilled water at a ratio of 1:15;
[0020] (4) Heat the extraction container to 80°C, maintain the temperature and stir continuously for 3 hours, filter, and collect the filtrate b;
[0021] (5) combining filtrate a and filtrate b to obtain filtrate c, and filtering filtrate c using a 0.45 μm filter membrane to obtain filtrate d;
[0022] (6) Concentrating the filtrate d to 1 / 4 of the original volume to obtain a concentrated solution;
[0023] (7) After deproteinization with Sevage reagent, the concentrate was transferred to an ultrafiltration device, filtered using a 10 kDa ultrafiltration membrane, and the retentate was collected;
[0024] (8) Add 4 times the volume of anhydrous ethanol of the retentate, stir evenly, and leave overnight;
[0025] (9) After centrifugation, the precipitate is separated and washed with ethanol;
[0026] (10) The washed precipitate is freeze-dried in vacuum to obtain purslane polysaccharide powder.
[0027] Preferably, the stem cells are bone marrow mesenchymal stem cells.
[0028] Secondly, the present invention provides a method for improving the Parkinson's disease therapeutic ability of stem cell exosomes, the method comprising the following steps:
[0029] (1) Bone marrow mesenchymal stem cells are evenly seeded into a cell culture dish;
[0030] (2) After the cells adhered, the medium was replaced with DMEM / F12 medium containing acetylated purslane polysaccharide and cultured under standard cell culture conditions;
[0031] (3) After the culture, the supernatant was collected and exosomes were extracted by differential centrifugation.
[0032] Preferably, the acetylated purslane polysaccharide is prepared by the above-mentioned preparation method of acetylated purslane polysaccharide;
[0033] In the DMEM / F12 medium, the concentration of the acetylated purslane polysaccharide is 100 μg / ml;
[0034] The culture time under the standard cell culture conditions is greater than or equal to 48 hours.
[0035] Preferably, the standard cell culture conditions are 37° C., 5% CO 2 ; and the culture time under the standard cell culture conditions is 48 h.
[0036] Secondly, the present invention provides a preparation for improving the Parkinson's disease therapeutic ability of exosomes, wherein the preparation is a DMEM / F12 medium preparation, wherein the DMEM / F12 medium preparation contains 100 μg / ml acetylated purslane polysaccharide, and the acetylated purslane polysaccharide is prepared by the preparation method of acetylated purslane polysaccharide described in claim 2.
[0037] Secondly, the present invention provides an exosome that improves the ability to treat Parkinson's disease, wherein the exosome is secreted by bone marrow mesenchymal stem cells treated with acetylated purslane polysaccharide;
[0038] The acetylated purslane polysaccharide is prepared by the above-mentioned preparation method of acetylated purslane polysaccharide.
[0039] Preferably, the exosomes are prepared according to the following preparation method:
[0040] (1) Bone marrow mesenchymal stem cells are evenly seeded into a cell culture dish;
[0041] (2) After the cells adhered, the culture medium was replaced with DMEM / F12 medium containing 100 μg / ml of the acetylated purslane polysaccharide and cultured under standard cell culture conditions for greater than or equal to 48 hours;
[0042] (3) After the culture, the supernatant was collected and exosomes were extracted by differential centrifugation.
[0043] The standard cell culture conditions were 37°C, 5% CO2.
[0044] Secondly, the present invention provides a drug for treating Parkinson's disease, characterized in that the drug consists of exosomes and normal saline;
[0045] Each 250 μL of the drug contained 50 μg of exosomes;
[0046] The exosomes are exosomes secreted by bone marrow mesenchymal stem cells treated with acetylated purslane polysaccharide;
[0047] The acetylated purslane polysaccharide is prepared by the above-mentioned preparation method of acetylated purslane polysaccharide;
[0048] The exosomes are prepared according to the following preparation method:
[0049] (1) Bone marrow mesenchymal stem cells are evenly seeded into a cell culture dish;
[0050] (2) After the cells adhered, the culture medium was replaced with DMEM / F12 medium containing 100 μg / ml of the acetylated purslane polysaccharide and cultured under standard conditions for greater than or equal to 48 hours;
[0051] (3) After the culture, the supernatant was collected and exosomes were extracted by differential centrifugation.
[0052] The beneficial effects of the present invention are:
[0053] The present invention provides an application of acetylated purslane polysaccharide in improving the ability of stem cell exosomes to treat Parkinson's disease. Experimental tests have shown that exosomes treated with acetylated purslane polysaccharide significantly improve the efficacy of improving Parkinson's disease symptoms compared with ordinary exosomes, especially in improving the motor coordination, balance ability and autonomous activity level of Parkinson's disease mice. This indicates that acetylated purslane polysaccharide may improve the effect of nerve repair by increasing the content of exosomes.
[0054] Secondly, exosomes treated with acetylated purslane polysaccharide not only show excellent effects in the treatment of Parkinson's disease, but also have the potential to be further developed as drugs for the treatment of nervous system diseases. This invention provides a new idea and method for the development of new neuroprotective agents and opens up a new direction for the application of exosomes in medicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] In order to better understand the content and implementation methods of the present invention, the present invention is further described below in conjunction with the accompanying drawings. The accompanying drawings are only used to illustrate certain embodiments of the present invention and do not limit the scope of the present invention;
[0056] Figure 1 Transmission electron microscopy images (scale bar 50 nm) of different exosomes prepared by the present invention (control group exosomes, treatment group a exosomes, treatment group b exosomes) are shown;
[0057] Figure 2 The effects of different exosome treatment groups (control group, experimental group a, experimental group b, and experimental group c) on cell survival rate in the 6-hydroxydopamine (6-OHDA)-induced neuronal cell injury model were demonstrated;
[0058] Figure 3 The average time that mice in different treatment groups (control group, model group, experimental group a, experimental group b, and experimental group c) stayed on the rotating rod in the rotating rod experiment was shown;
[0059] Figure 4 The figure shows the movement distance of mice in different treatment groups (control group, model group, experimental group a, experimental group b, and experimental group c) in the open field test. DETAILED DESCRIPTION
[0060] The optional embodiments of the present invention will be described in more detail below. Although the optional embodiments of the present invention have been described, it should be understood that the present invention can be implemented in various forms and should not be limited to the specific embodiments described herein. On the contrary, these embodiments are provided to make the present invention more thorough and complete, and to fully convey the scope of the present invention to those skilled in the art.
[0061] Biopolysaccharides are a class of high molecular weight compounds formed by sugar units connected by glycosidic bonds, which are widely found in animals, plants, microorganisms and algae. They have a variety of biological activities, such as antioxidant, anti-inflammatory, immunomodulatory and anti-tumor, and are widely used in the fields of medicine, food and biomaterials. Biopolysaccharides can not only directly exert biological activities, but also regulate cell behavior and signal transduction through interactions with other biomolecules. However, whether the treatment of polysaccharides can improve the ability of exosomes to treat Parkinson's disease has not been reported.
[0062] Example 1
[0063] (1) Place dried purslane into an extraction container and add distilled water at a ratio of 1:15;
[0064] (2) heating the extraction container to 80°C, maintaining the temperature and stirring continuously for 3 hours, filtering, and collecting the residue and filtrate a;
[0065] (3) Place the residue into an extraction container and add distilled water at a ratio of 1:15;
[0066] (4) Heat the extraction container to 80°C, maintain the temperature and stir continuously for 3 hours, filter, and collect the filtrate b;
[0067] (5) combining filtrate a and filtrate b to obtain filtrate c, and filtering filtrate c using a 0.45 μm filter membrane to obtain filtrate d;
[0068] (6) The filtrate d was transferred to a rotary evaporator and concentrated to 1 / 4 of the original volume at 60° C. to obtain a concentrated solution;
[0069] (7) After deproteinization with Sevage reagent, the concentrate was transferred to an ultrafiltration device, filtered using a 10 kDa ultrafiltration membrane, and the retentate was collected;
[0070] (8) Add 4 times the volume of anhydrous ethanol of the retentate, stir evenly, and leave overnight;
[0071] (9) 4000 rpm, after 10 min, the precipitate was separated and washed with ethanol;
[0072] (10) The washed precipitate is freeze-dried in vacuum to obtain purslane polysaccharide powder.
[0073] Example 2
[0074] (1) 200 mg of purslane polysaccharide was prepared into a 20 mg / mL purslane polysaccharide solution using 10 mL of distilled water;
[0075] (2) Using 0.1 mol / L sodium hydroxide solution, the pH was adjusted to 8, and 2 mL of acetic anhydride was added according to the material-liquid ratio of purslane polysaccharide to acetic anhydride of 1:10. During the addition process, 0.5 mol / L sodium hydroxide was used to control the pH of the reaction system in the range of 8-8.5;
[0076] (3) After reacting for 2.5 h, the pH was adjusted to 7 using 0.1 mol / L hydrochloric acid solution to terminate the reaction and obtain reaction solution a;
[0077] (4) The reaction solution a was transferred to a rotary evaporator and concentrated to 1 / 4 of the original volume at 60° C. to obtain a concentrated solution;
[0078] (5) After deproteinization with Sevage reagent, add 4 times the volume of anhydrous ethanol of the concentrate, stir evenly, and leave overnight;
[0079] (6) 4000 rpm, after 10 minutes, the precipitate was separated and washed with ethanol;
[0080] (7) freeze-drying the washed precipitate in a vacuum oven to obtain acetylated purslane polysaccharide powder;
[0081] (8) Using D-anhydrous glucose as the standard, the phenol-sulfuric acid method was used to determine the total sugar content of purslane polysaccharides before and after acetylation modification;
[0082] (9) The acetyl content was determined by acid-base titration. The sample was dissolved with sodium hydroxide and fully saponified. The unreacted base was titrated with hydrochloric acid. The acetyl content (A%) and degree of substitution (DS) were calculated according to the following formula:
[0083] A=(V0C0-V1C1)×0.043×100 / m; DS=132A / 4300-32A;
[0084] Wherein, A is the acetyl content; V0 (mL) represents the volume of the sodium hydroxide solution consumed; C0 (mol / L) represents the concentration of the NaOH solution consumed; V1 (mL) represents the volume of the hydrochloric acid solution consumed; C1 (mol / L) represents the concentration of the hydrochloric acid solution consumed; m (g) is the sample mass.
[0085] The results obtained were A=15.63 and DS=0.54.
[0086] Example 3
[0087] Obtaining exosomes prepared by different treatment methods
[0088] (1) Bone marrow mesenchymal stem cells of generation P3 were obtained and evenly inoculated into a pre-prepared cell culture dish. After the cells adhered to the wall, they were divided into three groups and treated with different conditions:
[0089] Control group: cultured with ordinary DMEM / F12 medium;
[0090] Treatment group a: cultured in DMEM / F12 medium containing 100 μg / ml purslane polysaccharide;
[0091] Treatment group b: The cells were cultured in DMEM / F12 medium containing 100 μg / ml acetylated purslane polysaccharide.
[0092] (2) Each group of cell culture dishes was placed back in the incubator and cultured under standard conditions of 37°C and 5% CO2 for 48 hours. During this period, the stability of the temperature, humidity and gas environment in the incubator was ensured to maintain the normal metabolism and secretory activity of the cells.
[0093] (3) After 48 hours of culture, the supernatant (culture medium) was carefully collected from each culture dish to ensure that the adherent cells were not disturbed and to prevent cells from falling off and entering the supernatant; the collected supernatants were marked as control group, treatment group a, and treatment group b for subsequent processing.
[0094] (4) The supernatant of each group was placed at 4°C and centrifuged at 300 g for 10 min to remove any dead cells that might be present in the supernatant.
[0095] (5) Carefully aspirate the supernatant and further centrifuge at 2000 g for 20 min to remove cell debris and larger particles.
[0096] (6) The supernatant was centrifuged again at 10,000 g for 30 min to remove large particulate matter such as large vesicles.
[0097] (7) The supernatant treated above was subjected to ultracentrifugation at 140,000 g for 90 minutes. After the centrifugation, the supernatant was carefully removed.
[0098] (8) Resuspend the precipitate with PBS to ensure that the precipitate is completely dissolved, and then centrifuge again at 140,000 g for 90 min to further purify the exosomes.
[0099] (9) Finally, the precipitate was resuspended in PBS (for cell experiments) or saline (for animal experiments), the concentration was determined by the BCA method, and the exosome suspension was diluted to 200 μg / mL to obtain the exosomes of the control group, the exosomes of treatment group a, and the exosomes of treatment group b.
[0100] Example 4
[0101] Detection of exosome morphology using transmission electron microscopy
[0102] (1) Take 10 μL of the control group exosomes, treatment group a exosomes, and treatment group b exosomes prepared in the example, and evenly drop them on the pre-prepared copper mesh.
[0103] (2) Let the copper mesh stand for 3 minutes to ensure that the exosomes are fully adsorbed on the surface of the mesh. Then, use dust-free paper or filter paper to gently absorb the excess floating liquid on the surface of the copper mesh to avoid excessive infiltration of the sample and affect the subsequent staining effect.
[0104] (3) Carefully add 10 μL of phosphotungstic acid solution onto the treated copper grid for staining;
[0105] (4) Leave the copper grid to stand for 1 minute to allow the stain to fully combine with the sample. Then, use dust-free paper or filter paper to gently absorb the excess staining solution to prevent solution residue from causing unclear imaging.
[0106] (5) The treated copper mesh was placed in a room temperature environment to dry for 5 minutes. After drying, a transmission electron microscope (TEM) was used to image and analyze the sample.
[0107] from Figure 1 The results show that the exosomes in the control group, the exosomes in the treatment group a, and the exosomes in the treatment group b prepared by the present invention all have the oval structure of the exosomes, indicating that the exosomes of the present invention are successfully extracted. Secondly, it can be seen that compared with the exosomes in the control group, the exosomes in the treatment group a and the exosomes in the treatment group b have larger diameters, and the diameter of the exosomes in the treatment group b is further enlarged compared with the treatment group a. It is speculated that the possible reason is that after stimulation with purslane polysaccharide or acetylated purslane polysaccharide, the exosomes released by the stem cells contain more contents, thereby increasing the volume of the exosomes.
[0108] Example 5
[0109] Effects of different exosomes on 6-hydroxydopamine-induced neuronal damage
[0110] 6-hydroxydopamine (6-OHDA) is a neurotoxin model commonly used in the study of Parkinson's disease. It selectively destroys dopaminergic neurons, so the present invention selects it to simulate the pathological process of Parkinson's disease.
[0111] (1) First, SH-SY5Y cells in the logarithmic growth phase were prepared into a single-cell suspension, and the cell density was adjusted to 2.5×10^5 cells per ml.
[0112] (2) Inoculate 100 μL of the cell suspension into each well of a 96-well plate, ensuring that the initial number of cells in each well is consistent; after inoculation, place the 96-well plate in a cell culture incubator and continue incubating under standard conditions until the cells are completely attached.
[0113] (3) Take 100 μL of the exosomes from the control group, treatment group a, and treatment group b, respectively, and add them to 2 mL of DMEM / F12 culture medium for dilution to prepare the exosome dilution solution of the control group, the exosome dilution solution of the treatment group a, and the exosome dilution solution of the treatment group b.
[0114] (4) After SH-SY5Y cells were completely attached to the 96-well plate, the original culture medium was removed; then, 100 μL of DMEM / F12 culture medium without exosomes was added to the control group and the model group, respectively, while the corresponding exosome dilutions were added to the experimental groups: the exosome dilutions of treatment group a were added to the experimental group a, the exosome dilutions of treatment group b were added to the experimental group b, and the exosome dilutions of treatment group c were added to the experimental group c.
[0115] (5) After 12 hours of exosome treatment, the culture medium in each well was carefully removed, and 100 μL of fresh DMEM / F12 culture medium was added to the control group, while DMEM / F12 culture medium containing 6-OHDA (100 μmol / L) was added to the model group and each experimental group (experimental group a, experimental group b, and experimental group c) to induce cell damage.
[0116] (6) After 24 hours of treatment, add 20 μL of MTT solution to each well and continue incubation for 4 hours to allow the mitochondria in the cells to reduce MTT to generate purple formazan crystals. After incubation, gently remove the MTT solution in the wells and add 150 μL of DMSO to each well to dissolve the formazan crystals. Oscillate the 96-well plate on an oscillator for 15 minutes to ensure that the formazan crystals are completely dissolved. Finally, use a microplate reader to measure the absorbance value of each well at a wavelength of 490 nm, and calculate the cell viability based on the absorbance data to evaluate the protective effect of exosomes in 6-OHDA-induced cell damage.
[0117] from Figure 2 The results clearly show that the cell survival rate of the model group (45.58%) was significantly lower than that of the control group, which indicates that this experiment successfully constructed a Parkinson's disease cell injury model and fully simulated the neural injury environment of the disease;
[0118] In the experimental groups pretreated with exosomes, the cell survival rates of experimental group a (58.38%), experimental group b (61.36%), and experimental group c (77.41%) were all higher than those of the model group, indicating that exosomes have a certain protective effect on 6-OHDA-induced neural injury. Specifically, the cell survival rate of experimental group b was slightly higher than that of experimental group a, but after statistical analysis, the difference between the two was not significant. This suggests that although purslane polysaccharides increase the volume of exosomes, the increase in their contents may not significantly enhance the function of exosomes in reducing neural injury.
[0119] Compared with experimental group a, the cell survival rate of experimental group c was significantly improved, indicating that the exosomes obtained after treatment with acetylated purslane polysaccharide showed a better effect in reducing 6-OHDA-induced neural damage. Acetylation treatment may further enhance the potential of exosomes in neuroprotection by enhancing their protective ability.
[0120] Example 6
[0121] Detecting the effects of different exosomes on Parkinson's mice
[0122] A. Construction of Parkinson's model and exosome processing
[0123] (1) Healthy male C57BL / 6 mice aged 8-10 weeks and weighing 25-30 g were randomly divided into 5 groups: control group, model group, experimental group a, experimental group b, and experimental group c, with 5 mice in each group;
[0124] (2) After the mice in the model group, experimental group a, experimental group b, and experimental group c were anesthetized, they were fixed on a brain stereotaxic instrument to ensure stability. The head was fully disinfected with iodine, and then the scalp was cut along the midline to expose the skull.
[0125] (3) After identifying and confirming the bregma point, the location of the drill hole was determined on the left side of the mouse using the coordinates of the bregma point 2.2 mm posterior, 1.4 mm left and right from the midline, and 4.7 mm subdural depth as reference. The microdrill was used to slowly drill the hole at the designated location, and the microinjection needle was carefully advanced to the predetermined coordinate position.
[0126] (4) After the needle reaches the target site, start to slowly inject 6-OHDA solution (4 μg, containing 0.2% ascorbic acid) at a constant speed and complete the injection within 2 minutes. To ensure complete distribution and absorption of the drug, after the injection is completed, the needle remains in place for 5 minutes and then slowly withdraws to reduce damage to surrounding tissues.
[0127] (5) After the operation, apply an appropriate amount of penicillin to the wound of the mouse to prevent infection. Then, use surgical thread to carefully suture the scalp to ensure that the wound is well closed;
[0128] (6) Finally, the mice were placed back in a clean cage and continued to be raised. Starting from the second day, the control group and the model group were injected with 250 μL of normal saline through the tail vein, and the experimental groups a, b, and c were injected with 250 μL (50 μg) of normal saline containing the exosomes of the control group, the exosomes of the treatment group a, and the exosomes of the treatment group b, respectively. The injections were given every other day for a total of 7 injections.
[0129] B. To evaluate the performance of mice in motor coordination and balance, we designed and implemented the rotarod test.
[0130] (1) After 14 days, the mice with different treatments were placed on a rotarod apparatus and the rotation speed was set to an initial low speed (2 rpm / min) to allow the mice to gradually adapt to the rotation of the rotarod. The training time for each mouse on the rotarod was no less than 5 minutes to ensure that all mice could maintain balance at this speed.
[0131] (2) The mouse was placed on a stationary rotarod. The rotarod started at an initial speed of 0 rpm / min and the speed was increased by 5 rpm / min every 30 seconds until the mouse could no longer maintain balance and fell off the rotarod. The maximum test time was 300 seconds.
[0132] (3) Record the staying time of each mouse at different speeds. If the mouse does not fall within the maximum test time, it is recorded as 300 seconds. Each mouse needs to be tested three times, with an interval of 1 hour between experiments.
[0133] (4) Calculate the average residence time of each mouse as an indicator of its motor coordination and balance ability.
[0134] C. In order to evaluate the performance of mice's voluntary activity level, we designed and implemented an open field test
[0135] (1) Place the open field test apparatus in a quiet, moderately lit laboratory. Clean the test apparatus thoroughly with 75% alcohol solution to ensure that any odor or residue that may affect the test results is eliminated.
[0136] (2) Before the experiment, mice with different treatments were placed in the experimental environment to adapt for 30 minutes to reduce the stress response caused by environmental changes.
[0137] (3) Place each mouse individually in the central area of the open field test apparatus and release the animal gently to avoid startling it with sudden movements.
[0138] (4) Start the experimental timer and use the video monitoring system to record the animal's behavior in the experimental device for 5 minutes.
[0139] (5) After each animal experiment, the experimental apparatus was cleaned with 75% alcohol solution to ensure that the smell and traces of the previous animal were eliminated to prevent the experimental results of the next animal from being affected.
[0140] (6) Use a computer to calculate the movement distance of mice and evaluate the level of autonomous movement of mice.
[0141] from Figure 3It can be clearly seen from the experimental results that compared with the control group (115s), the mice in the model group (55s) stayed significantly shorter in the rotarod test, which indicates that the Parkinson's disease mouse model constructed by the present invention effectively reduces the motor coordination and balance ability of the mice and successfully simulates the motor dysfunction characteristics of Parkinson's disease.
[0142] In the experimental groups injected with different exosomes, the mice in experimental group a (66s), experimental group b (70s) and experimental group c (89s) stayed on the rotating rod for different degrees compared with the model group. This result shows that the injection of exosomes can improve the motor coordination and balance ability of Parkinson's disease mice to a certain extent, suggesting that exosomes have a certain protective or therapeutic effect on motor dysfunction.
[0143] Further analysis of the results showed that although the rotarod time of mice in experimental group b was longer than that of experimental group a, this extension did not reach statistical significance, indicating that there was little difference in the effects of exosome treatment between the two groups. However, the rotarod time of mice in experimental group c was significantly prolonged, significantly better than that of experimental groups a and b. This result shows that the use of acetylated purslane polysaccharide treatment can effectively enhance the therapeutic effect of stem cell exosomes in enhancing the motor coordination and balance ability of Parkinson's disease mice.
[0144] and Figure 3 Similar results were obtained in Figure 4 The results showed that the movement distance of mice in the model group (487 mm) was significantly decreased compared with that in the control group (1553 mm), which further proved that the Parkinson's disease mouse model constructed by the present invention successfully reduced the level of autonomous activity of mice and exhibited typical movement dysfunction characteristics of Parkinson's disease.
[0145] In the experimental groups injected with different exosomes, the movement distance of mice in experimental group a (749mm), experimental group b (805mm) and experimental group c (1195mm) increased. This phenomenon shows that the injection of exosomes can improve the level of autonomous activity of Parkinson's disease mice to a certain extent, providing positive support for their recovery of motor function.
[0146] Further analysis showed that although the difference in movement distance between experimental group b and experimental group a increased, it did not reach statistical significance, indicating that the two groups of exosome treatments were equally effective in improving the motor ability of mice. However, the movement distance of mice in experimental group c was significantly better than that of experimental group a, showing a significant statistical difference. This result indicates that after treatment with acetylated purslane polysaccharide, the stem cell exosomes obtained showed a stronger therapeutic effect in enhancing the level of autonomous activity in Parkinson's disease mice. Moreover, compared Figure 3 and Figure 4The results show that the effect of stem cell exosomes obtained after treatment with acetylated purslane polysaccharide in treating the level of autonomous activity of mice is better than that of treating the motor coordination and balance ability of mice.
[0147] In summary, exosomes treated with acetylated purslane polysaccharide not only showed significant therapeutic effects in improving the motor coordination and balance ability of Parkinson's disease mice, but also showed stronger therapeutic potential in improving their autonomous activity levels. Therefore, exosomes treated with acetylated purslane polysaccharide are expected to be developed as an effective drug for the treatment of Parkinson's disease, providing a new treatment approach and strategy, bringing more hope for the recovery of patients.
Claims
1. An application of an acetylated polysaccharide in the preparation of a pharmaceutical preparation for improving the therapeutic ability of stem cell exosomes for Parkinson's disease, characterized in that: The acetylated polysaccharide is acetylated purslane polysaccharide.
2. The use according to claim 1, characterized in that: The preparation method of the acetylated purslane polysaccharide comprises the following steps: (1) preparing a purslane polysaccharide solution using distilled water; (2) adjusting the pH to 8, adding acetic anhydride according to the solid-liquid ratio of purslane polysaccharide to acetic anhydride of 1:10, and controlling the pH of the reaction system in the range of 8-8.5 during the addition process; (3) After reacting for 2.5 h, the pH was adjusted to 7 to terminate the reaction to obtain reaction solution a; (4) Concentrating the reaction solution a to 1 / 4 of the original volume to obtain a concentrated solution; (5) After deproteinization with Sevage reagent, add 4 times the volume of anhydrous ethanol of the concentrate, stir evenly, and leave overnight; (6) After centrifugation, the precipitate is separated and washed with ethanol; (7) The washed precipitate is freeze-dried in vacuum to obtain acetylated purslane polysaccharide powder.
3. The use according to claim 2, characterized in that: The preparation method of purslane polysaccharide comprises the following steps: (1) Place dried purslane into an extraction container and add distilled water at a ratio of 1:15; (2) heating the extraction container to 80°C, maintaining the temperature and stirring continuously for 3 hours, filtering, and collecting the residue and filtrate a; (3) Place the residue into an extraction container and add distilled water at a ratio of 1:15; (4) Heat the extraction container to 80°C, maintain the temperature and stir continuously for 3 hours, filter, and collect the filtrate b; (5) combining filtrate a and filtrate b to obtain filtrate c, and filtering filtrate c using a 0.45 μm filter membrane to obtain filtrate d; (6) Concentrating the filtrate d to 1 / 4 of the original volume to obtain a concentrated solution; (7) After deproteinization with Sevage reagent, the concentrate was transferred to an ultrafiltration device, filtered using a 10 kDa ultrafiltration membrane, and the retentate was collected; (8) Add 4 times the volume of anhydrous ethanol of the retentate, stir evenly, and leave overnight; (9) After centrifugation, the precipitate is separated and washed with ethanol; (10) The washed precipitate is freeze-dried in vacuum to obtain purslane polysaccharide powder.
4. The use according to claim 3, characterized in that: The stem cells are bone marrow mesenchymal stem cells.
5. A method for improving the Parkinson's disease therapeutic ability of stem cell exosomes, characterized in that: The method comprises the following steps: (1) Bone marrow mesenchymal stem cells are evenly seeded into a cell culture dish; (2) After the cells adhered, the medium was replaced with DMEM / F12 medium containing acetylated purslane polysaccharide and cultured under standard cell culture conditions; (3) After the culture, the supernatant was collected and exosomes were extracted by differential centrifugation.
6. The method according to claim 5, characterized in that The acetylated purslane polysaccharide is prepared by the preparation method of acetylated purslane polysaccharide described in claim 2; In the DMEM / F12 medium, the concentration of the acetylated purslane polysaccharide is 100 μg / ml; The culture time under the standard cell culture conditions is greater than or equal to 48 hours.
7. A preparation for improving the ability of exosomes to treat Parkinson's disease, characterized in that: The preparation is a DMEM / F12 culture medium preparation, which contains 100 μg / ml acetylated purslane polysaccharide. The acetylated purslane polysaccharide is prepared by the preparation method of acetylated purslane polysaccharide described in claim 2.
8. An exosome that improves the ability to treat Parkinson's disease, characterized in that: The exosomes are exosomes secreted by bone marrow mesenchymal stem cells treated with acetylated purslane polysaccharide; The acetylated purslane polysaccharide is prepared by the preparation method of acetylated purslane polysaccharide described in claim 2.
9. The exosome according to claim 8, characterized in that The exosomes are prepared according to the following preparation method: (1) Bone marrow mesenchymal stem cells are evenly seeded into a cell culture dish; (2) After the cells adhered, the culture medium was replaced with DMEM / F12 medium containing 100 μg / ml of the acetylated purslane polysaccharide and cultured under standard cell culture conditions for greater than or equal to 48 hours; (3) After the culture, the supernatant was collected and exosomes were extracted by differential centrifugation.
10. A drug for treating Parkinson's disease, characterized in that: The drug consists of exosomes and normal saline; Each 250 μL of the drug contained 50 μg of exosomes; The exosomes are exosomes secreted by bone marrow mesenchymal stem cells treated with acetylated purslane polysaccharide; The acetylated purslane polysaccharide is prepared by the preparation method of acetylated purslane polysaccharide described in claim 2; The exosomes are prepared according to the following preparation method: (1) Bone marrow mesenchymal stem cells are evenly seeded into a cell culture dish; (2) After the cells adhered, the cells were cultured in a DMEM / F12 medium containing 100 μg / ml of the acetylated purslane polysaccharide under standard cell culture conditions for greater than or equal to 48 hours; (3) After the culture, the supernatant was collected and exosomes were extracted by differential centrifugation.
